The Cancer Development and Progression (CDP) Program is one of three interactive research Programs of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA). The primary focus of the CDP Program is laboratory-based studies of fundamental problems in cancer etiology, but always with an eye towards translational potential. The major thematic areas in the CDP Program are (1) Genomic Integrity and Aging and (2) Hormones and Chronic Inflammation. The overarching scientific objectives of the CDP Program are to: (1) integrate basic and translational research in genomic integrity, age-related cancer susceptibility, hormone actions, and chronic inflammation to obtain a deeper and broader picture of cancer development and progression;(2) foster transdisciplinary, synergistic, and highly complementary collaboration between basic and translational research within the CDP Program and in the EDT and CPPS Programs;and (3) translate laboratory findings into novel approaches in cancer prevention and treatment. The CDP program is comprised of 31 members. Twenty-eight members represent eight departments within the School of Medicine at the UTHSCSA. Two members are from the University of Texas at Austin. The CDP Program members have $7,290,029 of peer-reviewed cancer-related funding (33 grants). Of those, $2,195,289 are from 10 NCI grants. Over the last funding period the CDP Program has 271 peer-reviewed cancer-related publications of which 26% are intra-programmatic collaborafions and 22% are inter-programmatic collaborations.
The Cancer Development and Progression (CDR) Program members perform cutting-edge laboratory-based cancer research to understand fundamental problems in cancer etiology with a continual focus on translational potential.
|Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20|
|Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970|
|Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40|
|Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232|
|Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor Î² Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185|
|Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014|
|Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82|
|Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289|
|Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190|
|Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10|
Showing the most recent 10 out of 853 publications